Trials / Completed
CompletedNCT04084184
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HGP1602 in Healthy Subjects
An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HGP1602 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HGP1602 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HGP1812 | Dapagliflozin (Forxiga) 10mg |
| DRUG | HGP1602 | Dapagliflozin 10mg |
Timeline
- Start date
- 2019-03-15
- Primary completion
- 2019-03-25
- Completion
- 2019-03-29
- First posted
- 2019-09-10
- Last updated
- 2019-09-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04084184. Inclusion in this directory is not an endorsement.